MedPath

Clinical Study of High-intensity Focused Ultrasound Tumor Treatment System(Super Knife) in the Treatment of Breast Cancer

Not Applicable
Recruiting
Conditions
Breast Cancer
Interventions
Device: a high-intensity focused ultrasound tumor treatment system (Super Knife)
Registration Number
NCT06210529
Lead Sponsor
Shengjing Hospital
Brief Summary

Breast cancer is the most common cancer diagnosed among women and is the second leading cause of cancer death among women after lung cancer. The treatment methods of breast cancer include surgery, chemotherapy, radiotherapy and so on. The investigators discover a High-intensity focused ultrasound therapy to treat breast tumor, which is a non-invasive method.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
12
Inclusion Criteria

ECOG Performance Status of 0-1; Histological confirmed invasive breast cancer; Breast cancer tumor measuring ≥2 cm in maximal diameter and a single lesion as measured by mammogram, breast ultrasound, or breast MRI; Breast tumor's borders from the skin are greater than 1 cm; No lymph node or distant metastasis; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, Platelets ≥ 50 × 109/L, Hemoglobin ≥ 9.0 g/dl iv; Serum creatinine ≤1.5 x upper limit of normal (ULN); AST ≤ 2.5 x ULN, ALT ≤ 2.5 x ULN; Left ventricular ejection fraction ≥ 50%.

Exclusion Criteria

Inflammatory breast cancer, bilateral breast cancer, or occult breast cancer; Any kind of prior treatment for breast cancer, including chemotherapy, radiotherapy, endocrine therapy and so on; Pregnant and lactating women; Patients who have participated in other clinical trials.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group B (treatmen twice)a high-intensity focused ultrasound tumor treatment system (Super Knife)-
Group A (treatmen once)a high-intensity focused ultrasound tumor treatment system (Super Knife)-
Primary Outcome Measures
NameTimeMethod
Pathological complete response (pCR)1 month after surgery

pCR is defined as the absence of residual invasive cancer in the breast and the lymph nodes.

Secondary Outcome Measures
NameTimeMethod
Objective response rateIn the first month, the second month, the third month

The percentage of patients whose therapeutic intervention has led to a complete response, partial response.

Disease control rateIn the first month, the second month, the third month

The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease.

Adverse events1 month after surgery

Adverse events during and after the treatment

Trial Locations

Locations (1)

Shengjing Hospital of China Medical University

🇨🇳

Shenyang, Liaoning, China

© Copyright 2025. All Rights Reserved by MedPath